Hoth Therapeutics (HOTH) announced a significant expansion of its CLEER-001 Phase 2a clinical trial with the addition of Regis Clinical Research as a new enrolling site. Located in Miami, Florida, Regis joins the growing CLEER-001 investigational site network as surging patient demand outpaces capacity at existing sites – a direct reflection of the compelling early clinical results HT-001 has produced and the desperate unmet need it addresses.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOTH:
- Hoth Therapeutics receives U.S. notice of allowance for Exon-skipping therapy
- Hoth Therapeutics’ HT-VA GDNF shows superior efficacy in obesity
- Hoth Therapeutics confirms it holds no cryptocurrency assets
- Hoth Therapeutics’ HT-001 shows 100% response in EFGR-treated cancer patients
- Hoth Therapeutics receives approval for HT-KIT cancer program patent in China